# Long Term Follow-up Study for Patients Enrolled on the BP-004 Clinical Study

> **NCT03733249** · PHASE1,PHASE2 · TERMINATED · sponsor: **Bellicum Pharmaceuticals** · enrollment: 187 (actual)

## Conditions studied

- Acute Lymphoblastic Leukemia
- Leukemia, Acute Myeloid (AML), Child
- Lymphoma, Non-Hodgkin
- Myelodysplastic Syndromes
- Primary Immunodeficiency
- Anemia, Aplastic
- Hemoglobinopathies
- Cytopenia
- Fanconi Anemia
- Diamond Blackfan Anemia
- Thalassemia
- Anemia, Sickle Cell

## Interventions

- **DRUG:** Rimiducid
- **BIOLOGICAL:** rivogenlecleucel

## Key facts

- **NCT ID:** NCT03733249
- **Lead sponsor:** Bellicum Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2017-01
- **Primary completion:** 2020-06-30
- **Final completion:** 2023-04-14
- **Target enrollment:** 187 (ACTUAL)
- **Last updated:** 2023-09-26


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03733249

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03733249, "Long Term Follow-up Study for Patients Enrolled on the BP-004 Clinical Study". Retrieved via AI Analytics 2026-06-04 from https://api.ai-analytics.org/clinical/NCT03733249. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*